Point72 Hong Kong LTD Vir Biotechnology, Inc. Transaction History

Point72 Hong Kong LTD

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$7.63 - $12.66 $96,122 - $159,490	12,598 Added 180.64%	19,572 $174,000
Q1 2024 May 15, 2024	SELL	$8.6 - $11.9 $56,579 - $78,290	-6,579 Reduced 48.54%	6,974 $70,000
Q4 2023 Feb 14, 2024	BUY	$7.76 - $10.29 $105,171 - $139,460	13,553 New	13,553 $136,000
Q3 2022 Nov 14, 2022	BUY	$18.26 - $31.1 $358,662 - $610,866	19,642 New	19,642 $379,000
Q2 2022 Aug 15, 2022	SELL	$19.08 - $26.7 $130,411 - $182,494	-6,835 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$21.19 - $40.01 $144,833 - $273,468	6,835 New	6,835 $176,000
Q3 2021 Nov 15, 2021	SELL	$34.9 - $54.54 $264,018 - $412,595	-7,565 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$38.75 - $51.0 $293,143 - $385,815	7,565 New	7,565 $358,000

218

87M

127K

1.19M

Ticker VIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 132,638,000
Market Cap $982M
Description
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 fo...

Get notified when there are updates to the investment portfolio of Point72 Hong Kong LTD, based on Form 13F filings with the SEC.

Stay updated on Point72 Hong Kong LTD with notifications on news.